Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as low as $0.28. Conatus Pharmaceuticals shares last traded at $0.30, with a volume of 79,484 shares.

CNAT has been the topic of several recent research reports. HC Wainwright reaffirmed a “hold” rating and set a $1.50 price objective on shares of Conatus Pharmaceuticals in a report on Friday, May 3rd. Zacks Investment Research raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $4.91.

The stock has a market cap of $9.95 million, a P/E ratio of -0.51 and a beta of 2.18. The company has a 50-day moving average price of $0.31 and a two-hundred day moving average price of $1.09.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.10. The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $7.00 million. Conatus Pharmaceuticals had a negative return on equity of 60.61% and a negative net margin of 42.26%. On average, analysts forecast that Conatus Pharmaceuticals Inc will post -0.48 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hikari Power Ltd increased its position in shares of Conatus Pharmaceuticals by 19.8% during the 1st quarter. Hikari Power Ltd now owns 200,488 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 33,200 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Conatus Pharmaceuticals by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 33,827 shares during the last quarter. Wedbush Securities Inc. bought a new position in shares of Conatus Pharmaceuticals during the 1st quarter valued at approximately $46,000. D. E. Shaw & Co. Inc. increased its position in shares of Conatus Pharmaceuticals by 50.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 62,163 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 20,826 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Conatus Pharmaceuticals by 13.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,861,987 shares of the biotechnology company’s stock valued at $485,000 after purchasing an additional 223,092 shares during the last quarter. 24.94% of the stock is currently owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Story: How liquidity affects the bid-ask spread

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.